Print
Two small California biotechs, Cellerant and Achaogen, have secured new multi-million dollar federal defense contracts to develop technologies for combating potential bioterrorism threats with clinical stage therapies.
San Carlos-based Cellerant won a five-year contract valued at $153 million with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
Read More
Deals
Another Specialty Buy for PfizerFoldRX acquisiton adds to neuroscience portfolio. Read More.Deals
A Big Bet on BiofuelsShell and Cosan joint venture moves closer to reality. Read More.Deals
Roche Bets Big on AileronPartners see promise in peptides for tackling tough diseases. Read More.Deals
Roche Dominates the Deal FlowThe Swiss biopharma announces a new acquisition and a drug discovery partnership. Read More.Deals
Life Technologies to Buy Ion Torrent for $375 MillionDeal, which could grow to $725 million if milestones are reached, heats up competition in low-cost sequencing. Read More.Deals
Deals on a RollAspen’s acquisition leads a busy week of deals worth up to $4.5 billion to life sciences companies. Read More.Deals
Aspen Unburdens Sigma with Pharmaceutical Division BuyDeals gives South African generic drugmaker foothold in Australia. Read More.Initial Public Offerings
Renewables Fuel IPO QueueTwo companies developing alternatives to petroleum file to go public. Read More.Deals
Deal Making Takes a VacationSlow week is stirred by a few smaller deals. Read More.Mergers and Acquisitions
Endo to Buy Penwest for $168 millionDeal frees Endo from royalty payments and gives it access to two experimental drugs for rare diseases. Read More.Initial Public Offerings
Rough HaircutTrius slashes offering to get out the door. Read More.Deals
Two Companies Complete IPOs; Two Enter the QueueTrius and NuPathe scale back their offering price to complete their deals. Read More.Deals
Shire moves to acquire MovetisThe $560 million deal bolsters the specialty pharma’s gastrointestinal business. Read More.Initial Public Offerings
IPO Market Sizzles - In China Podcast: August 2, 2010 Read More.Mergers and Acquisitions
Charles River Calls off WuXi DealInvestors kill the $1.6 billion acquisition. Read More.
.jpg)
.gif)
.gif)
.png){kind=small}
- Sanofi Chief Extends Hand to Bypass Genzyme `Brick Wall'
Bloomberg - U.S. Court Rules Against Obama’s Stem Cell Policy
The New York Times - Takeda Says Lifestyle-Disease Drugs Will Drive Growth
Bloomberg - Study Says Brain Trauma Can Mimic Lou Gehrig’s Disease
The New York Times - Two New Paths to the Dream: Regeneration
The New York Times - Medical Device Makers Face Revamped U.S. Rules for Approvals
Bloomberg - Pfizer May Gain as U.S. Devises Speedy Alternative to Animal Safety Tests
Bloomberg - Judge lets Virginia healthcare challenge proceed
Reuters - F.D.A. Clears Way for Embryonic Stem Cell Trial Using Patients
The New York Times - Technologies Help Adult Children Monitor Aging Parents
The New York Times